Metastatic Cancer Vanishes in Boy After Two Experimental Shots

A three-year-old boy with advanced liver cancer saw complete tumor clearance after two experimental CAR T cell infusions, with no hospitalization between doses.

A three-year-old boy with metastatic hepatoblastoma—cancer that spreads to multiple organs—showed complete tumor clearance after two CAR T cell infusions targeting glypican-3 (GPC3). Imaging confirmed the disappearance of liver and lung tumors within two weeks of treatment, with the boy remaining cancer-free for at least 12 months. The therapy, engineered to express IL-15 and IL-21 and include a drug-activated kill switch for safety, required no hospitalization between doses. Baylor College of Medicine led the trial, which aims to recruit 30 patients aged 1–21 years. The case was published in the New England Journal of Medicine.

This approach represents a potential shift for metastatic cancers that typically have limited treatment options. The CAR T cells were designed to target a specific protein (GPC3) on cancer cells while minimizing systemic immune activation—a mechanism that could reduce severe side effects like neurotoxicity. However, the results are based on a single patient case study. The therapy’s effectiveness for tumors outside the liver/lung region, or for cancers lacking GPC3, remains unproven. Long-term risks of engineered cells expanding beyond control are also unknown.

If scalable, this could reduce mortality for aggressive cancers that currently lack effective treatments. But for now, it remains a promising but narrow pathway—requiring further validation in larger trials before becoming a widely available option. The next critical step is whether the therapy’s safety and efficacy can be replicated across diverse patient populations with different tumor types and sizes.

Source: Singularity Hub